EGFR Non-Small Cell Lung Cancer: Karen's Patient Story
This lung cancer diagnosis at a glance
- Subtype
- Non-Small Cell Lung Cancer
- Biomarkers
- EGFR mutation
- Sex
- Female
- Treatment
- targeted therapy
- Outcome
- In Memory
Treatment course, step by step
- COVID-19 lockdown-era lung cancer diagnosis
- non-small cell lung adenocarcinoma with EGFR mutation
- targeted therapy that Karen described as extending her life.
What happened, in summary
Karen Knetter learned she had non-small cell lung adenocarcinoma with an EGFR mutation during the COVID-19 lockdown period. While she was in the hospital, her oncologist’s encouragement helped her feel that she had a full team behind her. Karen described that support as a “wolf pack,” made up of her medical team, decades of lung cancer research, and the targeted therapy that was extending her life. Karen used her 2-year anniversary after diagnosis to advocate for better lung cancer funding, detection, and treatment. She wanted people to understand that lung cancer affects smokers, former smokers, and never-smokers, and that stigma should not determine research priorities or access to modern care. She also emphasized that targeted therapy exists because of research investment and that more funding could improve future outcomes. Karen passed away on September 7, 2024, 4 years after her lung cancer diagnosis. Her experience also highlights how biomarker testing can shape treatment options and give patients more time. Her story is best understood as both a patient experience and an advocacy message about EGFR testing, targeted therapy, and the need to fund lung cancer research. She wanted future patients to benefit from better detection, less stigma, and more research-backed options.
Where this story comes from
This is a lay summary of an account first published by Lung Cancer Research Foundation. Read the original in full
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team.